JP2024500920A - 抗ｉｌ１ｒａｐ抗体 - Google Patents

抗ｉｌ１ｒａｐ抗体 Download PDF

Info

Publication number
JP2024500920A
JP2024500920A JP2023538679A JP2023538679A JP2024500920A JP 2024500920 A JP2024500920 A JP 2024500920A JP 2023538679 A JP2023538679 A JP 2023538679A JP 2023538679 A JP2023538679 A JP 2023538679A JP 2024500920 A JP2024500920 A JP 2024500920A
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
binding fragment
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023538679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024500920A5 (https=
Inventor
ダーヴィド・リーバリ
カミラ・リュードバリ・ミールードゥ
ガーブリエル・スヴェンソン・ビルケダル
サーラ・ラティーキ
シェル・ショーストローム
カーリン・ヴォン・ヴァーケンフェルト
ケイトリオーナ・グレンバリ
Original Assignee
カンタージア アクチエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2105933.2A external-priority patent/GB202105933D0/en
Application filed by カンタージア アクチエボラーグ filed Critical カンタージア アクチエボラーグ
Publication of JP2024500920A publication Critical patent/JP2024500920A/ja
Publication of JP2024500920A5 publication Critical patent/JP2024500920A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2023538679A 2020-12-23 2021-12-22 抗ｉｌ１ｒａｐ抗体 Pending JP2024500920A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20216926.4 2020-12-23
EP20216926 2020-12-23
GBGB2105933.2A GB202105933D0 (en) 2021-04-26 2021-04-26 Anti-IL1rap antibody
GB2105933.2 2021-04-26
EP21212368 2021-12-03
EP21212368.1 2021-12-03
PCT/EP2021/087338 WO2022136569A1 (en) 2020-12-23 2021-12-22 Anti-il1rap antibody

Publications (2)

Publication Number Publication Date
JP2024500920A true JP2024500920A (ja) 2024-01-10
JP2024500920A5 JP2024500920A5 (https=) 2025-01-06

Family

ID=79731073

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023538679A Pending JP2024500920A (ja) 2020-12-23 2021-12-22 抗ｉｌ１ｒａｐ抗体

Country Status (9)

Country Link
US (2) US11479610B2 (https=)
EP (1) EP4267625A1 (https=)
JP (1) JP2024500920A (https=)
KR (1) KR20230123962A (https=)
AU (1) AU2021405730A1 (https=)
CA (1) CA3202942A1 (https=)
IL (1) IL303922A (https=)
MX (1) MX2023007611A (https=)
WO (1) WO2022136569A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020035577A1 (en) 2018-08-16 2020-02-20 Cantargia Ab Anti-il1rap antibody compositions
EP4267625A1 (en) * 2020-12-23 2023-11-01 Cantargia AB Anti-il1rap antibody
CA3220913A1 (en) 2021-05-21 2022-11-24 Leo Pharma A/S Anti il-1 receptor accessory protein antibodies
AR130550A1 (es) 2022-09-21 2024-12-18 Sanofi Biotechnology Anticuerpo anti-il-1r3 humanizado y métodos de uso
CN116284401B (zh) * 2023-02-20 2024-09-24 中国人民解放军军事科学院军事医学研究院 人源抗il-1r3抗体及其应用
EP4705340A1 (en) 2023-05-05 2026-03-11 Otsuka Pharmaceutical Co., Ltd. Anti-il1rap antibodies
CN120775048A (zh) * 2024-04-02 2025-10-14 信达生物制药(苏州)有限公司 抗il1rap抗体以及其用途
WO2026022232A1 (en) 2024-07-24 2026-01-29 Almirall, S.A. Il-1rap inhibitor for treating or preventing hidradenitis suppurativa

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018519364A (ja) * 2015-06-26 2018-07-19 マブ ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツングＭＡＢ Ｄｉｓｃｏｖｅｒｙ ＧｍｂＨ モノクローナル抗ＩＬ−１ＲＡｃＰ抗体
JP2019534705A (ja) * 2016-10-16 2019-12-05 セレラント セラピューティクス インコーポレイテッド 抗ｉｌ１−ｒａｐ抗体
WO2020035577A1 (en) * 2018-08-16 2020-02-20 Cantargia Ab Anti-il1rap antibody compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
US9403906B2 (en) 2011-01-19 2016-08-02 Cantargia Ab Method of treatment of a solid tumor with interleukin-1 accessory protein antibody
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
AU2018312563A1 (en) 2017-08-01 2020-03-12 City Of Hope Anti-IL1RAP antibodies
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
EP4267625A1 (en) * 2020-12-23 2023-11-01 Cantargia AB Anti-il1rap antibody

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018519364A (ja) * 2015-06-26 2018-07-19 マブ ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツングＭＡＢ Ｄｉｓｃｏｖｅｒｙ ＧｍｂＨ モノクローナル抗ＩＬ−１ＲＡｃＰ抗体
JP2019534705A (ja) * 2016-10-16 2019-12-05 セレラント セラピューティクス インコーポレイテッド 抗ｉｌ１−ｒａｐ抗体
WO2020035577A1 (en) * 2018-08-16 2020-02-20 Cantargia Ab Anti-il1rap antibody compositions

Also Published As

Publication number Publication date
MX2023007611A (es) 2023-07-12
CA3202942A1 (en) 2022-06-30
IL303922A (en) 2023-08-01
US12043666B2 (en) 2024-07-23
KR20230123962A (ko) 2023-08-24
AU2021405730A1 (en) 2023-07-06
AU2021405730A9 (en) 2025-03-20
US11479610B2 (en) 2022-10-25
WO2022136569A1 (en) 2022-06-30
US20230108007A1 (en) 2023-04-06
US20220242950A1 (en) 2022-08-04
EP4267625A1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
US12043666B2 (en) Anti-IL1RAP antibody
JP6827411B2 (ja) 新規の抗体及びその使用
US11673962B2 (en) Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab
JP6396488B2 (ja) 抗ヒトインターロイキン−１受容体アクセサリータンパク質（ｉｌ１ ｒａｐ）抗体およびその使用
JP2021526022A (ja) 抗インターロイキン１７ａ抗体、医薬組成物、およびその使用
US20250074978A1 (en) Antibodies for il-17c
US12534533B2 (en) Anti-chemokine like receptor 1 humanized antibodies and their therapeutic applications
KR20230166120A (ko) 새로운 tnfr2 결합 분자
CN116724055A (zh) 抗il1rap抗体
KR20260007604A (ko) 항-il1rap 항체
JP2023515480A (ja) 抗ｉｌ－２抗体、その抗原結合断片及びその医薬用途
JP2021513357A (ja) ネコＭｃＤｏｎｏｕｇｈ肉腫（ＦＭＳ）様チロシンキナーゼ３受容体リガンド（ＦＬＴ３Ｌ）に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260210

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260306

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20260410